Phibro Animal Health Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

37.70$ +3.0% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Income Statement

Phibro Animal Health Corporation (PAHC) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 397 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement PAHC
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	188	192	190	195	193	206	209	212	200	218	206	204	190	214	211	186	195	206	212	220	215	233	240	255	233	245	246	255	231	250	263	273	260	309	348	379	364	374	384	397	1,518
Cost of Revenue	127	128	129	132	130	139	140	144	134	150	141	139	132	145	141	125	131	138	143	150	150	162	168	177	164	167	170	178	164	171	184	186	177	207	243	269	244	241	258	262	1,006
Gross Profit	61	63	61	63	63	67	69	68	66	69	65	65	58	69	70	61	64	68	69	70	65	71	72	78	69	77	76	77	68	79	80	87	83	102	105	110	120	133	125	134	512
Research & Development	0.0	0.0	0.0	11	0.0	0.0	0.0	10.0	0.0	0.0	–	12	–	–	–	14	–	–	–	18	–	–	–	21	–	–	–	24	–	–	–	29	–	–	–	24	–	–	–	–	–
Selling, General & Administrative	39	41	31	40	41	43	43	41	43	43	42	53	48	49	48	42	48	48	49	51	50	48	52	56	55	62	57	53	69	63	60	69	66	76	71	76	69	82	81	86	318
Total Operating Expenses	39	41	31	40	41	43	43	41	43	43	42	53	48	49	48	42	48	48	49	51	50	48	52	56	55	62	57	53	68	63	60	69	66	76	71	76	71	78	77	86	313
Operating Income	22	23	30	24	22	24	26	26	23	26	23	12	10	20	21	18	16	20	20	19	15	22	19	23	14	16	19	24	-0.7	16	20	18	18	26	34	34	48	54	48	48	198
Interest Expense	4.6	4.4	4.3	3.7	3.4	3.3	3.3	3.6	3.2	3.5	3.4	3.6	3.8	3.9	3.7	2.6	2.3	2.6	2.3	3.2	3.9	4.0	2.3	3.1	4.9	6.9	7.9	8.8	9.2	9.4	9.3	5.7	8.2	9.2	13	8.5	13	13	11	10	48
Pre-Tax Income	18	19	26	17	19	21	24	24	23	20	20	9.2	3.6	17	19	16	17	16	18	16	9.6	24	27	12	5.4	12	15	21	-12	3.6	13	6.4	9.6	4.8	30	24	36	36	32	32	137
Income Tax Expense	5.4	5.9	2.8	1.8	3.1	14	4.5	1.4	6.4	5.3	4.7	0.4	1.1	5.0	5.2	11	4.2	3.3	5.6	-1.0	3.1	6.1	9.1	4.9	1.6	4.9	5.1	9.9	-4.0	2.3	4.5	5.7	2.6	1.7	8.8	6.6	9.7	9.0	8.3	11	38
Net Income	12	13	24	15	16	7.0	20	22	16	15	15	8.8	2.5	12	14	5.6	12	13	12	17	6.5	17	18	7.5	3.9	7.2	10	11	-8.0	1.3	8.4	0.8	7.0	3.2	21	17	27	27	24	22	100
EBITDA	29	31	29	27	30	32	33	34	30	31	29	20	15	29	31	27	27	27	29	27	20	34	38	24	17	25	28	35	2.2	18	28	21	27	26	51	45	63	62	56	56	236

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings